

Claims

1. Double-strand DNA oligonucleotides, wherein one of
5 the two DNA strands provides a sequence according
to SEQ ID NO: 1, 2, 7 to 10 or 15 to 34, and the
complementary DNA strand provides the sequence
complementary to the these.
- 10 2. Double-strand DNA oligonucleotides according to
claim 1 as pharmaceutical agents.
3. Use of double-strand, transcription-factor-AP-1-
binding DNA oligonucleotides, and of double-strand
15 DNA oligonucleotides according to SEQ ID NO: 1 to
36 for the manufacture of a pharmaceutical agent
for the prevention and/or treatment of acute and
chronic transplant rejection, acute and chronic
graft-versus-host disease (GvHD) and
20 ischaemia/reperfusion damage of organs following a
surgical intervention.